We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.71B
AUM Growth
-$646M
Cap. Flow
+$157K
Cap. Flow %
0%
Top 10 Hldgs %
52.04%
Holding
130
New
26
Increased
23
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$76.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.9M
3
FOLD
Amicus Therapeutics
FOLD
+$33.6M
4
AMRN
Amarin Corp
AMRN
+$25M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$21.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
2
ARRY
Array Biopharma Inc
ARRY
+$48.1M
3
BPMC
Blueprint Medicines
BPMC
+$28.5M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24M
5
QURE icon
uniQure
QURE
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
2 Miscellaneous 1.64%
3 Consumer Staples 1.29%
4 Financials 0.46%
5 Consumer Discretionary 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.2B
$366M 9.86%
4,059,900
+36,038
+0.9% +$3.37M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$285M 7.68%
5,875,726
+100,000
+2% +$5.21M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$258M 6.96%
3,314,606
+415,000
+14% +$38.9M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$4.24B
$200M 5.4%
11,014,702
-900,425
-8% -$19.9M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$197M 5.32%
24,609,700
+3,100,214
+14% +$33.6M
BBIO icon
6
BridgeBio Pharma
BBIO
$13.4B
$144M 3.88%
6,706,268
– –
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$131M 3.52%
3,264,152
-243,071
-7% -$11.2M
ATNX
8
DELISTED
Athenex, Inc. Common Stock
ATNX
$131M 3.52%
536,762
+45,656
+9% +$14.9M
AMRN
9
Amarin Corp
AMRN
$294M
$116M 3.12%
381,804
+71,741
+23% +$25M
DOVA
10
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$104M 2.79%
3,708,705
+155,645
+4% +$2.52M
MGTX icon
11
MeiraGTx Holdings
MGTX
$1.23B
$103M 2.76%
6,433,277
+425,531
+7% +$9.9M
QTNT
12
DELISTED
Quotient Limited Ordinary Shares
QTNT
$83.8M 2.26%
269,726
– –
NVRO
13
DELISTED
NEVRO CORP.
NVRO
$83.8M 2.26%
974,773
-162,992
-14% -$12.3M
SLDB icon
14
Solid Biosciences
SLDB
$897M
$69.8M 1.88%
449,987
+188,172
+72% +$21.3M
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
$69.8M 1.88%
+3,217,522
New +$76.1M
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$64.9M 1.75%
883,264
-329,467
-27% -$28.5M
ZYME icon
17
Zymeworks
ZYME
$1.86B
$59.2M 1.6%
2,388,890
+20,000
+0.8% +$501K
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$59M 1.59%
1,130,511
+30,000
+3% +$1.6M
ADMA icon
19
ADMA Biologics
ADMA
$1.93B
$51.3M 1.38%
11,521,102
– –
VRCA icon
20
Verrica Pharmaceuticals
VRCA
$78.7M
$50.3M 1.36%
341,041
– –
NEPT
21
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$47.8M 1.29%
9,598
+3,247
+51% +$21.1M
VBIV
22
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$46M 1.24%
1,531,719
+666,667
+77% +$14M
KOD icon
23
Kodiak Sciences
KOD
$2.07B
$45.1M 1.21%
3,135,199
– –
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
$43.6M 1.18%
953,129
-427,042
-31% -$24M
ALLO icon
25
Allogene Therapeutics
ALLO
$594M
$42.1M 1.13%
1,543,790
– –
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Perceptive Advisors held 130 positions worth $3.71B, down 15% from $4.36B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Perceptive Advisors's Q3 2019 filing shows 26 new, 23 increased, 15 reduced and 21 closed positions. Its largest new stake was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M. The largest sale was Ascendis Pharma A/S, an estimated $54.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q3 2019 buy was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $38.9M increase.
  • Perceptive Advisors's biggest Q3 2019 reduction was Blueprint Medicines, cutting an estimated $28.5M.
  • Perceptive Advisors fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $54.5M.
  • Perceptive Advisors's ten largest holdings make up 52% of its $3.71B portfolio in Q3 2019.
  • Perceptive Advisors opened 26 new positions and closed 21 in Q3 2019.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $3.71B.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.